Different Clinical Significance of Pre- and Post-treatment Plasma Epstein-Barr Virus DNA Load in Nasopharyngeal Carcinoma Treated with Radiotherapy

Clinical Oncology

Volumn 23, Issue 2, 2011, Pages 128-133

  Hou, Xue ^a,b   Zhao, Chong ^b   Guo, Ying ^b   Han, Fei ^b   Lu, Li Xia ^b   Wu, Shao Xiong ^b   Li, Su ^b   Huang, Pei Yu ^b   Huang, He ^b   Zhang, Li ^b  

^a SHANGHAI CHEST HOSPITAL   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Distant metastasis; Epstein Barr virus DNA; Nasopharyngeal carcinoma; Tumour volume

Indexed keywords

CISPLATIN; FLUOROURACIL; OXALIPLATIN; VIRUS DNA;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; EPSTEIN BARR VIRUS; FEMALE; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ASSAY; REAL TIME POLYMERASE CHAIN REACTION; TUMOR VOLUME; VIRUS LOAD;

ADULT; AGED; DNA, VIRAL; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR BURDEN; VIRAL LOAD;

EID: 79251644435     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2010.09.001     Document Type: Article

References (29)

1. Al-Sarraf M., Leblanc M., Giri P.G., et al. Chemoradiotherapy versus radiotherapy in patients with nasopharyngeal cancer: phase III randomized intergroup study 0099. J Clin Oncol 1998, 16:1310-1317.
2. Chi K.H., Chang Y.C., Guo W.Y., et al. A phase III study of adjuvant chemotherapy in advanced nasopharyngeal carcinoma patients. Int J Radiat Oncol Biol Phys 2002, 52:1238-1244.
3. Chan A.T., Ngan R., Teo P., et al. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst 2005, 97(7):536-539.
4. Lee A.W., Lau W.H., Tung S.Y., et al. Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 trial by the Hong Kong Nasopharyngeal Cancer Study Group. J Clin Oncol 2005, 28:6966-6975.
5. Zhang L., Zhao C., Peng P.J., et al. Phase III study comparing standard radiotherapy with or without weekly oxaliplatin in treatment of locoregionally advanced nasopharyngeal carcinoma: preliminary results. J Clin Oncol 2005, 23(33):8461-8468.
6. Langendijk J.A., Leemans C.R., Buter J., et al. The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature. J Clin Oncol 2004, 22:4604-4612.
7. Feng B.J., Huang W., Shugart Y.Y., et al. Genome-wide scan for familial nasopharyngeal carcinoma reveals evidence of linkage to chromosome 4. Nat Genet 2002, 31:395-399.
8. Zeng M.S., Li D.J., Liu Q.L., et al. Genomic sequence analysis of Epstein-Barr virus strain GD1 from a nasopharyngeal carcinoma patient. J Virol 2005, 79(24):15323-15330.
9. Mutirangura A., Pornthanakasem W., Theamboonlers A., et al. Epstein-Barr viral DNA in serum of patients with nasopharyngeal carcinoma. Clin Cancer Res 1998, 4:665-669.
10. Lo Y.M., Chan L.Y., Lo K.W., et al. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res 1999, 59:1188-1191.
11. Lin J.C., Wang W.Y., Chen K.Y., et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 2004, 350:2461-2470.
12. Shao J.Y., Li Y.H., Gao H.Y., et al. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma. Cancer 2004, 100:1162-1170.
13. Shao J.Y., Zhang Y., Li Y.H., et al. Comparison of Epstein-Barr virus DNA level in plasma, peripheral blood cell and tumor tissue in nasopharyngeal carcinoma. Anticancer Res 2004, 24(6):4059-4066.
14. Lo Y.M., Chan A.T., Chan L.Y., et al. Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA. Cancer Res 2000, 60:6878-6881.
15. Chan A.T., Lo Y.M., Zee B., et al. Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst 2002, 94:1614-1619.
16. Leung S.F., Chan A.T., Zee B., et al. Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type. Cancer 2003, 98:288-291.
17. Fleming I.D., Cooper J.S., Henson D.E., et al. AJCC cancer staging manual 1997, Lippincott-Raven, Philadelphia, p. 31-39. 5th ed.
18. Li-xia Lu, Chong Zhao, Fei Han, et al. Initial study of the clinical target volume delineation for radiotherapy of nasopharyngeal carcinoma. Clin J Radiat Oncol 2005, 14(2):81-85.
19. Chong Zhao Improved local control with intensity modulated radiation therapy in patients with nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2004, 60(Suppl. 1):S317.
20. Royston P., Altman D.G. Regression using fractional polynomials of continuous covariates: parsimonious parametric modelling (with discussion). Appl Stat 1994, 43(3):429-467.
21. Sauerbrei W., Royston P. Building multivariable prognostic and diagnostic models: transformation of the predictors by using fractional polynomials. J R Stat Soc Ser A 1999, 162:71-94.
22. Sauerbrei W., Meier H.C., Benner A., et al. Multivariable regression model building by using fractional polynomials: description of SAS, STATA and R programs. Comput Stat Data Anal 2006, 50(12):3464-3485.
23. Benner A. MFP: Multivariable fractional polynomials. R News 2005, 5(2):20-23.
24. Lo Y.M., Chan L.Y., Chan A.T., et al. Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Res 1999, 59:5452-5455.
25. Lo Y.M., Leung S.F., Chan L.Y., et al. Kinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharygeal carcinoma. Cancer Res 2000, 60:2351-2355.
26. Peng P.J., Zhao C., Liao H., et al. Correlation between the kinetics of plasma EBV DNA levels and clinical response during treatment in patients with nasopharyngeal carcinoma. Chin J Can 2002, 21(8):817-822.
27. Hong R.L., Lin C.Y., Ting L.L., et al. Comparison of clinical and molecular surveillance in patients with advanced nasopharyngeal carcinoma after primary therapy. Cancer 2004, 100:1429-1437.
28. William I.W., Anthony P.W., Raymond W.M., et al. Quantitative analysis of plasma cell-free Epstein-Barr virus DNA in nasopharyngeal carcinoma after salvage nasopharyngectomy: a prospective study. Head Neck 2004, 26:878-883.
29. Chan K.C., Chan A.T., Leung S.F., et al. Investigation into the origin and tumoral mass correlation of plasma Epstein-Barr virus DNA in nasopharyngeal carcinoma. Clin Chem 2005, 51:2192-2195.